ArticleBMC genomics2025
Sex reversal induced by 17β-estradiol may be achieved by regulating the neuroendocrine system of the Pacific white shrimp Penaeus vannamei.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Melatonin suppresses the plasma calcium level in female goldfish during the late and post-reproductive stages.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDue to sexual dimorphism in growth of penaeid shrimp, all-female cultivation is desirable for the aquaculture industry. 17β-estradiol (E2) has the potential to induce the male-to-female sex reversal of decapod species. However, the mechanisms behind it remain poorly understood. This study aimed to investigate the effects of E2 immersion on the neuroendocrine system (the eyestalk ganglia, brain, thoracic ganglia, and ventral nerve cord) of the Pacific white shrimp Penaeus vannamei through comparative transcriptomic analyses of the control males (CM), E2-treated males without sex reversal (EM), and neo-females (NF).
resultsImmersion in E2 at 2 mg/l from post-larvae (PL) 5 to 85 results in a skewed female-to-male ratio of 2.56: 1. The survival rate remains unaffected by E2 exposure, while a notable inhibition in growth is exclusively observed in the EM compared to the CM group. The transcriptome analysis result indicates that the observed retardation in growth of the EM may be attributed to the potential neuronal damage caused by the excessive neurotransmission, which in turn disrupts the PI3K-Akt signaling and cell cycle pathways. In contrast, the negatively regulated pathways of neuroactive ligand-receptor interaction and the dopaminergic synapse in the NF group suggest a potential impact of E2 on neuroplasticity through the modulation of neuroregulator binding and signaling, which affects the establishment of morphological differences and gender identity. Moreover, the activation of steroidogenesis and the inhibition of the insulin signaling may be associated with the success of E2-induced sex reversal. With these findings, a proposed mechanism of neuroendocrine system in decapods in response to E2 exposure is presented.
conclusionsThe present study represents a first step in understanding the effects of E2 on the neuroendocrine system at the molecular level. The observed retardation in growth in the EM group may be attributed to the potential for neuronal damage and disruptions in the cell cycle and PI3K-Akt signaling pathways. Furthermore, the success of E2-induced sex reversal may be associated with the downregulation of neuroactive ligand-receptor interaction, dopaminergic synapse, and insulin signaling pathways, as well as the activation of steroidogenesis. These findings provide new insights into the mode of action of E2, and underscore the potential for large-scale production of all-female stocks in P. vannamei.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.